Search results for "OUTCOME"

showing 10 items of 5148 documents

The Role of Third Ventriculostomy in the Management of Obstructive Hydrocephalus

2003

Objective: Endoscopic third ventriculostomy (ETV) is an effective treatment for occlusive hydrocephalus caused by an obstruction of the CSF flow in the aqueduct or the posterior fossa. We evaluated the factors age, pathology and surgical technique on the results of the ETV. Methods: Between November 1992 and October 2000 171 ETV have been performed in 159 patients. The follow-up was evaluated in 150 patients. The age ranged from 10 days to 77 years (mean age 35 years). The hydrocephalus was caused by benign aqueductal stenosis in 77 patients, space-occupying lesions in 59, by intraventricular hemorrhages in 11, and by other causes in 3 patients. The trajectory was planned in 31 patients by …

AdultMaleVentriculostomymedicine.medical_specialtyAdolescentmedicine.medical_treatmentObstructive hydrocephalusVentriculostomyStereotaxic TechniquesCentral nervous system diseasePostoperative ComplicationsOutcome Assessment Health CaremedicineHumansChildAgedThird Ventriclemedicine.diagnostic_testbusiness.industryAge FactorsInfant NewbornEndoscopic third ventriculostomyInfantEndoscopyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryHydrocephalusEndoscopyHemiparesisAqueductal stenosisChild PreschoolFemaleSurgeryNeurology (clinical)medicine.symptombusinessFollow-Up StudiesHydrocephalusmin - Minimally Invasive Neurosurgery
researchProduct

Changes in physical activity among coronary and hypertensive patients: A longitudinal study using the Health Action Process Approach

2017

Objectives: Physical activity (PA) is a key factor in cardiovascular disease prevention. Through the Health Action Process Approach (HAPA), the present study investigated the process of change in PA in coronary patients (CPs) and hypertensive patients (HPs). Design: Longitudinal survey study with two follow-up assessments at 6 and 12 months on 188 CPs and 169 HPs. Main outcome measures: Intensity and frequency of PA. Results: A multi-sample analysis indicated the equivalence of almost all the HAPA social cognitive patterns for both patient populations. A latent growth curve model showed strong interrelations among intercepts and slopes of PA, planning and maintenance self-efficacy, but chan…

AdultMaleVolitionSettore M-PSI/01 - Psicologia GeneraleGerontologyLongitudinal studyPhysical activityessential arterial hypertensionCoronary DiseaseModels PsychologicalDevelopmental psychologyacute coronary syndromeYoung Adult03 medical and health sciences0302 clinical medicinecardiovascular diseaseHumansMedicineLongitudinal Studies030212 general & internal medicineHealth Action Process ApproachExerciseApplied PsychologyAgedPhysical activity; Health Action Process Approach; cardiovascular diseases; acute coronary syndrome; essential arterial hypertension030505 public healthbusiness.industryPhysical activityHealth action process approachPublic Health Environmental and Occupational HealthOutcome measuresSurvey researchGeneral MedicineGeneral ChemistryMiddle AgedSelf Efficacycardiovascular diseasesHypertensionFemaleDisease prevention0305 other medical sciencebusinessSocial cognitive theoryFollow-Up Studies
researchProduct

THE USE OF ARGENTUM-QUARTZ SOLUTION IN PRIMARY OR RECURRENT PERIANAL FISTULAS: FIRST EXPERIENCE ON THREE CASES

2019

Primary perianal fistulous pathology represents a painful condition often noticeable in patients affected by Crohn's disease or Ulcerative colitis. It causes difficult defecation and can evolve in perianal abscess that should be urgently ascertained and drained. The present work aims to propose Argentum-Quartz® as valid non-surgical therapeutic treatment in order to reach a more comfortable perianal fistula healing. In fact, our preliminary data allow us to consider Argentum Quartz® ideally employable for treatment of perianal fistulas associated or not with IBDs, representing a reliable sphincter-sparing solution.

AdultMaleWound HealingAnal CanalQuartzMiddle AgedCRYPTITIS PERIANAL SUPPURATIVE FISTULAS ARGENTUM QUARTZ SOLUTION SETONSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCrohn DiseaseHumansRectal FistulaColitis UlcerativeFemaleOrgan Sparing Treatments
researchProduct

Value of the sperm deoxyribonucleic acid fragmentation level, as measured by the sperm chromatin dispersion test, in the outcome of in vitro fertiliz…

2005

To determine the prognostic value of sperm DNA fragmentation levels, as measured by the sperm chromatin dispersion (SCD) test, in predicting IVF and ICSI outcome.Double-blind prospective study.University-affiliated private IVF setting.A total of 85 couples undergoing infertility treatment with IVF/ICSI.Analysis of DNA fragmentation by the SCD test in 170 aliquots obtained from the ejaculate and from the processed semen used for assisted reproductive technologies (ART).Percentage of spermatozoa with fragmented DNA was statistically correlated with embryo quality and reproductive success.Fertilization rate was inversely correlated with DNA fragmentation (r = -0.245 P = .045). Higher DNA fragm…

AdultMaleZygotemedicine.medical_treatmentEmbryonic DevelopmentReproductive technologyDNA FragmentationFertilization in VitroBiologyIntracytoplasmic sperm injectionAndrologyPredictive Value of TestsPregnancymedicineHumansEmbryo ImplantationSperm Injections IntracytoplasmicFragmentation (cell biology)reproductive and urinary physiologyIn vitro fertilisationPronucleusurogenital systemObstetrics and GynecologySpermSpermatozoaChromatinBlastocystTreatment OutcomeReproductive MedicineFertilizationembryonic structuresDNA fragmentationFemaleEmbryo qualityCell NucleolusFertility and sterility
researchProduct

Testosterone-Lowering Medication and Its Association With Recidivism Risk in Individuals Convicted of Sexual Offenses

2020

For a particular subgroup of individuals with severe paraphilic disorders and a high risk of sexual recidivism, the combination of sex drive–reducing medications and psychotherapy is a promising treatment approach. The present quasi-experimental study aims at comparing differences in clinical characteristics and dynamic risk factors between persons receiving (+TLM, n = 38) versus not receiving (−TLM, n = 22) testosterone-lowering medications (TLMs). Individuals receiving TLM were more frequently diagnosed with paraphilic disorders. Neither the criminal history nor average risk scores differed between the two groups. In the +TLM, Stable-2007 scores showed a stronger decrease after TLM treat…

AdultMaleantiandrogensTreatment durationPsychopathySelf-ControlRisk FactorsGermanyparaphilic disordermedicineHumansTestosteroneAssociation (psychology)General PsychologyAgedAverage riskDuration of TherapyRecidivismParaphilic DisordersSex Offensesrisk assessmentAndrogen Antagonistssexual offender treatmentTestosterone (patch)ArticlesCriminalsMiddle Agedmedicine.diseaseGnRH-agonistsCriminal historyPsychotherapyPsychiatry and Mental healthTreatment OutcomeRecidivismRisk assessmentPsychologyClinical psychologySexual Abuse
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I

2018

The quantification of enzyme activity in the patient treated with enzyme replacement therapy (ERT) has been suggested as a tool for dosage individualization, so we conducted a study to evaluate the relationship between glucocerebrosidase activity and clinical response in patients with Gaucher disease type I (GD1) to ERT. The study included patients diagnosed with GD1, who were being treated with ERT, and healthy individuals. Markers based on glucocerebrosidase activity measurement in patients' leucocytes were studied: enzyme activity at 15 min. post-infusion (Act75 ) reflects the amount of enzyme that is distributed in the body post-ERT infusion, and accumulated glucocerebrosidase activity …

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyDiseaseToxicologySeverity of Illness IndexGastroenterology03 medical and health sciencesGlucocerebrosidase activity0302 clinical medicineStatistical significanceInternal medicineLeukocytesHumansMedicineEnzyme Replacement TherapyIn patientProspective Studies030212 general & internal medicineInverse correlationAgedEnzyme AssaysPharmacologyGaucher DiseaseDose-Response Relationship Drugbiologybusiness.industryArea under the curvenutritional and metabolic diseasesGeneral MedicineEnzyme replacement therapyMiddle AgedEnzyme assayTreatment Outcome030220 oncology & carcinogenesisbiology.proteinGlucosylceramidaseFemalebusinessBiomarkersFollow-Up StudiesBasic & Clinical Pharmacology & Toxicology
researchProduct

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

2007

The European Task Force for Neuronopathic Gaucher Disease (NGD) met in 2006 to review its 2001 guidelines. Fifty-five patients from five European countries were reviewed; 29 were male and 26 female. The majority of the patients were homozygous for the L444P mutation. All had been on enzyme replacement therapy (ERT). However, there was considerable variation in the dose of ERT, as well as an uneven distribution of risk factors. Thus, the oldest patients were on the lowest doses, and several had had a total splenectomy, while the youngest patients had a high proportion of compound heterozygosity and were on the highest doses, and very few had had a splenectomy. This heterogeneity rendered ana…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsHeterozygoteTime FactorsAdolescentmedicine.medical_treatmentSplenectomyEnzyme TherapyDiseaseCompound heterozygosityCentral nervous system diseaseOlder patientsRisk FactorsGeneticsmedicineTotal splenectomyHumansChildGenetics (clinical)Intelligence TestsChemotherapyGaucher Diseasebusiness.industryHomozygotenutritional and metabolic diseasesEnzyme replacement therapymedicine.diseaseSurgeryTreatment OutcomeChild PreschoolGlucosylceramidaseFemaleNervous System DiseasesbusinessJournal of inherited metabolic disease
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct